Form D · Biotechnology

KOP Therapeutics Corp.

Vancouver, A1 · CIK 0001793824

Offering snapshot reported Jan 31, 2020 · SEC filing

Reported sold: $114K
Investors reported: 2
Minimum accepted: $0
First sale: Oct 22, 2019

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Jan 31, 2020	Amendment	$114,000	$0vs Dec 19, 2019	2	SEC filing
Dec 19, 2019	Amendment	$114,000	-$630vs Nov 15, 2019	2	SEC filing
Nov 15, 2019	Initial	$114,630	No comparison	3	SEC filing

Offering details

Securities: Equity, Option to acquire
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-353470

The two sales in the U.S. totaled $150,000 Canadian dollars. The Bank of Canada exchange rate on December 4, 2019, was 1 CAD = 0.76 USD. Accordingly, the Company received US $114,000.

Source: Form D, filed Jan 31, 2020. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
Tibor Fancis Gajdics	Director, Executive
Ian Hollis Mann	Director
Mark Richard Redcliffe	Director, Executive
Marco Andres Strub	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

Suite 404 815 Hornby Street
Vancouver, A1, V6Z 2E6